Ye Weiguo reported option exercise involving 3,500 derivative units of GYRE THERAPEUTICS, INC. at $0.00 for $0 on May 22, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Operating Officer
Chief Operating Officer
Filed May 27, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
3,500Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
901,395Direct
Trade date
May 22, 2026Option exercise
Filed
May 27, 2026, 4:01 PM ET5-day reporting delay
Accession
0001140361-26-022980Code M · Transaction 89647
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 22, 2026Option exercise3,500$0.75$2,625Trade 89643
May 26, 2026Option exercise4,000$0.75$3,000Trade 89645
May 26, 2026Option exercise4,000$0.00$0Trade 89648
May 22, 2026Sell3,500$6.08−$21,280Trade 89644
May 26, 2026Sell4,000$6.10−$24,400.40Trade 89646
6 transaction rows in this filing. Joint filers share the same rows.

GYRE price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
GYRE · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +31%1w ago +11%1d ago +4.4%
Returns since7d −3.9%30d +6.3%90d +13%180d1y

Footnotes in full

F1: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.04 to $6.1051. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. F2: These options are vested in full.